A new preprint covered by Healthline analyzed more than 15 million medical records and identified 1,039 people with documented use of BPC-157, the synthetic peptide nicknamed "Wolverine," finding a roughly 33-fold increase in new users between 2020 and 2026. The results have not yet been published in a peer-reviewed journal.

BPC-157 is a synthetic 15-amino-acid peptide sold online for wellness, and it picked up its nickname from claims that it speeds healing the way the X-Men character does. Proponents say the injectable promotes injury recovery, pain relief and tissue healing, and some advocate "stacking" it with TB-500.

Who is actually using it

Lead author Venky Soundararajan, PhD, of nference told Healthline that use is "largely hidden in clinical narrative rather than conventional prescription data," which is why prescription records missed it. The share of newly documented users who were male rose from 57% in 2020 to 70% in 2026, a trend he described as statistically significant, with the population skewing younger each year.

Nearly 33% of patients in the cohort reported using BPC-157 for pain relief, against just 4% for performance enhancement. That ratio undercuts the gym-supplement framing: Soundararajan said the appeal appears strongest among patients still symptomatic after chronic or previously treated musculoskeletal problems.

What the clinical evidence looks like

Across the 1,039 patients, 27% reported improvements, with pain relief documented in 183, wound or tissue healing in 38, and functional return in 34. Those are retrospective chart notes, not trial endpoints, and the study could not estimate incidence or safety because adverse events are likely underreported.

The formal literature is thinner still. A 2025 systematic review found the field dominated by preclinical work and low-grade human evidence with insufficient clinical safety data, and the human studies that exist are tiny: a 2021 retrospective knee-pain study followed 16 participants with no control group, and a 2025 intravenous safety pilot involved two people.

The FDA vote everyone is reading wrong

An FDA advisory panel voted 8 to 6 in July, with one abstention, to add BPC-157 in free-base and acetate forms to the Section 503A bulk substances list, making it eligible for pharmacy compounding. That is not approval, and the agency has not made final regulatory decisions on peptides.

Sports medicine specialist Bert Mandelbaum, MD, of Cedars-Sinai was blunt with Healthline: "There is zero indication that BPC-157 has any efficacy for pain," and the safety profile is not understood. He called the panel's decision "ridiculous" and likened the peptide's rise to a Ponzi scheme promoted by influencers who exploit the gap between hope and knowledge.

Bottom line

The interesting finding here is not that BPC-157 works, because the records cannot show that. It is that a third of documented users came to it through unresolved pain, which is a signal about unmet clinical need that the eligibility fight has mostly talked past.